Akers Biosciences Inc (AKR)

This US company’s shares are traded by us as on the LSE. Income from them will not be treated as eligible for a reduced rate of tax. Learn more

AKR Share PerformanceMore

52 week high255.00 01/12/16
52 week low65.00 14/08/17
52 week change -150.00 (-65.22%)
4 week volume25,140 25/07/17

Media for (AKR)

Presenter: Ray, Akers, Co-Founder & Executive Chairman
Presenter: Ray, Akers, Co-Founder & Executive Chairman

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Akers Bio revenues up 10%

Akers Biosciences' total revenues rose by 10% $1,865,112 in the six months to the end of June while overheads were reduced b...

Half-year Report

RNS Number: 9768N Akers Biosciences, Inc. 15 August 2017 August 15, 2017 This announcement contains inside information Akers Biosciences, Inc. Financial Results for the Six Months Ended June 30, 2017 Total Revenues Up By 10% - Gross Profit Up By 10% - Overhead Lowered By 10% Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Co...

Akers Bio in equity issue

Akers Biosciences has issued 10,000 shares of the company's restricted common stock to Michael Warhol, a medical adviser...

Issue of Equity

RNS Number: 7215N Akers Biosciences, Inc. 11 August 2017 August 11, 2017 Akers Biosciences, Inc. Issue of Equity Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, announces that application will be made for 10,000 shares of the Company's restricted common stock of no pa...

Akers Bio resolutions passed at AGM

Akers Biosciences has confirmed that all resolutions proposed at its annual general meeting in Philadelphia yesterday were...

Result of AGM

RNS Number: 3407N Akers Biosciences, Inc. 08 August 2017 August 8, 2017 Akers Biosciences, Inc. Result of Annual General Meeting Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, announces that, at the Company's Annual General Meeting held yesterday in Philadelphia...

Akers Bio second quarter sales jump

Akers Biosciences said its second quarter sales were among the strongest since the company's admission to NASDAQ Capita...

Trading Update and Notice of Q2 Results

RNS Number: 0747N Akers Biosciences, Inc. 03 August 2017 August 3, 2017 Akers Biosciences, Inc. Trading Update & Notice of Q2 Results Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (" Akers Bio " or the "Company"), a developer of rapid health information technologies, announces that sales in the second quarter ended June 30, 2017 were among the stro...

Equity Research (AKR)

Akers Biosciences Inc.
Physiomics* (PYC.L) 0.04p £1.22m The computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials...
Akers Biosciences Inc.
ValiRx (Val.L) 39p £4.37m The life science company, which focuses on clinical stage cancer therapeutic development has received regulatory approval for its VAL401 Phase IIB Clinical Trial in Georgia...

Latest discussion posts More

  • Re: RNS : new PIFA agreement

    Maybe turned the corner here
  • RNS : new PIFA agreement

    Looks like a potentially lucrative agreement with a group of up to 300 New York hospitals to introduce the PIFA ...
  • Exciting RNS just out

    Worth noting in particular that First Check are a subsidiary of the mighty Alere ...

Users' HoldingsMore

Users who hold Akers Biosciences Inc also hold..

Codes & Symbols